ELV logo

Elevance Health, Inc. Stock Price

NYSE:ELV Community·US$82.1b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 211 Fair Values set on narratives written by author

ELV Share Price Performance

US$378.07
-38.62 (-9.27%)
US$387.85
Fair Value
US$378.07
-38.62 (-9.27%)
2.5% undervalued intrinsic discount
US$387.85
Fair Value
Price US$378.07
AnalystConsensusTarget US$387.85
AnalystHighTarget US$441.98
NateF US$390.54

ELV Community Narratives

·
Fair Value US$387.85 2.5% undervalued intrinsic discount

ELV: Margin Recovery Will Drive Upside Despite ACA Headwinds And Premium Increases

0users have liked this narrative
0users have commented on this narrative
109users have followed this narrative
·
Fair Value US$441.98 14.5% undervalued intrinsic discount

Aging Trends And Digital Integration Will Expand Managed Care Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Fair Value
·
Fair Value US$390.54 3.2% undervalued intrinsic discount

ELV Market Outlook

1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
ELV logo
Elevance Health

ELV Market Outlook

Elevance Health, Inc. (NYSE: ELV) is a prominent player in the health benefits industry, offering a range of services including medical, pharmaceutical, dental, and behavioral health plans.Read more

View narrative
US$390.54
3.2% undervalued intrinsic discount
Fair Value
Revenue
6.79% p.a.
Profit Margin
3.69%
Future PE
13.33x
Price in 2029
US$546.7
US$331
14.2% overvalued intrinsic discount
Revenue
0.7% p.a.
Profit Margin
3.15%
Future PE
12.07x
Price in 2029
US$403.48
US$441.98
14.5% undervalued intrinsic discount
Revenue
2.57% p.a.
Profit Margin
3.49%
Future PE
14.81x
Price in 2029
US$539.18
US$387.85
2.5% undervalued intrinsic discount
Revenue
1.8% p.a.
Profit Margin
3.16%
Future PE
14.66x
Price in 2029
US$473.15

Trending Discussion

Updated Narratives

ELV logo

ELV Market Outlook

Fair Value: US$390.54 3.2% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ELV logo

ELV: Regulatory And Margin Risks Will Pressure 2026 Earnings Visibility

Fair Value: US$331 14.2% overvalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ELV logo

ELV: 2026 CMS Sanction Resolution Will Support Medicare Advantage Margin Recovery

Fair Value: US$441.98 14.5% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet and pays a dividend.

0 Risks
4 Rewards

Elevance Health, Inc. Key Details

US$200.4b

Revenue

US$148.5b

Cost of Revenue

US$51.9b

Gross Profit

US$46.6b

Other Expenses

US$5.2b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
24.14
25.89%
2.62%
72.3%
View Full Analysis

About ELV

Founded
2001
Employees
96615
CEO
Gail Boudreaux
WebsiteView website
www.elevancehealth.com

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Recent ELV News & Updates

Narrative Update Apr 30

ELV: Regulatory And Margin Risks Will Pressure 2026 Earnings Visibility

The updated analyst price target for Elevance Health edges to $331 from $332, as analysts factor in slightly stronger revenue growth and profit margin assumptions, along with a modestly lower future P/E multiple, following a mix of recent upgrades, raised targets, and a few cautious revisions across the Street. Analyst Commentary Street research on Elevance Health has been mixed, with several firms lifting price targets while others trim expectations or shift to a more cautious stance.

Recent updates

No updates